These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 8363996)
1. Current issues in the management of nausea and vomiting. Gralla RJ Ann Oncol; 1993; 4 Suppl 3():3-7. PubMed ID: 8363996 [TBL] [Abstract][Full Text] [Related]
2. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Sorbe BG Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123 [TBL] [Abstract][Full Text] [Related]
3. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy. Bruntsch U; Rüfenacht E; Parker I; Drechsler S; de Bruijn K Ann Oncol; 1993; 4 Suppl 3():25-9. PubMed ID: 8363995 [TBL] [Abstract][Full Text] [Related]
4. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Simpson K; Spencer CM; McClellan KJ Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164 [TBL] [Abstract][Full Text] [Related]
5. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120 [TBL] [Abstract][Full Text] [Related]
6. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis. Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119 [TBL] [Abstract][Full Text] [Related]
8. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Malik I; Moid I; Khan Z; Hussain M Am J Clin Oncol; 1999 Apr; 22(2):126-30. PubMed ID: 10199444 [TBL] [Abstract][Full Text] [Related]
9. Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. Otten J; Hachimi-Idrissi S; Balduck N; Maurus R Semin Oncol; 1994 Oct; 21(5 Suppl 9):17-9. PubMed ID: 9113122 [TBL] [Abstract][Full Text] [Related]
10. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Gershanovich M; Kolygin B; Pirgach N Ann Oncol; 1993; 4 Suppl 3():35-7. PubMed ID: 8363998 [TBL] [Abstract][Full Text] [Related]
11. An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Sorbe B; Hallén C; Frankendal B Cancer Chemother Pharmacol; 1994; 33(4):298-302. PubMed ID: 8281622 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of tropisetron (Navoban) in controlling emesis induced in children by anti-cancer therapy. Rosso P; Cordero di Montezemolo L; Vivenza C; Nasi C; Tonello M; Valle P; Madon E Tumori; 1994 Dec; 80(6):459-63. PubMed ID: 7900236 [TBL] [Abstract][Full Text] [Related]
13. The development of tropisetron in its clinical perspective. de Bruijn KM Ann Oncol; 1993; 4 Suppl 3():19-23. PubMed ID: 8363994 [TBL] [Abstract][Full Text] [Related]
14. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Sorbe B Ann Oncol; 1993; 4 Suppl 3():39-42. PubMed ID: 8363999 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. Chang TC; Hsieh F; Lai CH; Tseng CJ; Cheng HH; Li CL; Michael BJ; Soong YK Cancer Chemother Pharmacol; 1996; 37(3):279-85. PubMed ID: 8529290 [TBL] [Abstract][Full Text] [Related]
16. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR; Hickok JT; Rosenthal SN Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113 [TBL] [Abstract][Full Text] [Related]
17. Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy. Bleiberg H; Hulstaert F; Buyse M; De Keyser P Anticancer Drugs; 1998 Oct; 9(9):773-7. PubMed ID: 9840722 [TBL] [Abstract][Full Text] [Related]
18. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Gregory RE; Ettinger DS Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240 [TBL] [Abstract][Full Text] [Related]
19. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Lee CR; Plosker GL; McTavish D Drugs; 1993 Nov; 46(5):925-43. PubMed ID: 7507039 [TBL] [Abstract][Full Text] [Related]
20. The anti-emetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation. Or R; Drakos P; Nagler A; Naparstek E; Kapelushnik J; Cass Y Support Care Cancer; 1994 Jul; 2(4):245-8. PubMed ID: 8087443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]